March 16, 2020 / 11:57 AM / 12 days ago

BRIEF-Eli Lilly Receives FDA Breakthrough Therapy Designation For Baricitinib For The Treatment Of Alopecia Areata

March 16 (Reuters) - Incyte Corp, Eli Lilly :

* LILLY RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR BARICITINIB FOR THE TREATMENT OF ALOPECIA AREATA

* ELI LILLY AND COMPANY- FDA HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO BARICITINIB FOR TREATMENT OF ALOPECIA AREATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below